lipid disorder vaccine / VLP Biotech - LARVOL DELTA

Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia. (PubMed, Circulation) - "ATS7vac is a novel atherosclerosis vaccine that also alleviates in-stent restenosis. The application of ATS7vac would be a complementary therapeutic avenue to the current lipid-lowering strategy for atherosclerotic disease."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • APOE • THBS1

Promoting athero-protective immunity by vaccination with low density lipoprotein-derived antigens. (PubMed, Atherosclerosis) - "Indeed, several such oxidized LDL tolerance vaccines have shown promising results in animal models of atherosclerosis. This review will discuss the experimental background for development of atherosclerosis vaccines based on LDL-derived antigens as well as the challenges involved in translating these findings into clinical application."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Immune Modulation • Inflammation • APOB

Vaccination against atherosclerosis. (PubMed, Curr Opin Immunol) - "Several candidate antigens for atherosclerosis vaccine development have been identified and have been shown to reduce atherosclerosis in animal models. In this review, we focus on two different types of atherosclerosis vaccines: antibody-inducing and regulatory T cell-inducing."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Myocardial Infarction

The unconventional side of vaccines (Biospectrumasia) - AVANT Immunotherapeutics developed a vaccine that works by eliciting neutralizing antibodies to CETP raising HDL; AFFiRiS has an atherosclerosis vaccine in pre-clinical development that induces antibodies against CETP

Review • Dyslipidemia

Vaccination Strategies and Immune Modulation of Atherosclerosis. (PubMed, Circ Res) - "In this review, we will discuss the experimental and clinical data supporting the possibility of developing immune-based therapies for lowering cardiovascular risk. We will also summarize ongoing clinical studies and discuss the challenges associated with developing an effective and safe atherosclerosis vaccine."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Immune Modulation • Immunology • Inflammation • Oncology

Opportunities for an atherosclerosis vaccine: From mice to humans. (PubMed, Vaccine) - "In this review, we discuss the status and opportunities for a human atherosclerosis vaccine. We describe (1) some of the immunomodulatory therapeutic interventions tested in atherosclerosis (2) the immune targets identified in pre-clinical and clinical investigations (3) immunization strategies evaluated in animal models (4) past and ongoing clinical trials to examine the safety and efficacy of human atherosclerosis vaccines and (5) strategies to improve and optimize vaccination in humans (antigen selection, formulation, dose and delivery)."

Journal • Preclinical

Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity (clinicaltrials.gov) - P3; N=300; Recruiting; Sponsor: Immunitor LLC; Trial completion date: Dec 2018 ➔ Dec 2019; Trial primary completion date: Dec 2018 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date